Delaying the Inevitable: New Hope for Preventing Type 1 Diabetes

For over a century, a diagnosis of type 1 diabetes has meant a lifetime of insulin injections.But a fundamental shift is underway, moving the focus from managing the disease to preventing it. new therapies, coupled with increasingly elegant early detection methods, offer the potential to delay – and perhaps even halt – the progression of this autoimmune condition, paving the way for an insulin-free future.

The Silent Autoimmune Attack

Type 1 diabetes isn’t caused by a lack of insulin, but by the immune system mistakenly attacking and destroying the insulin-producing cells in the pancreas. Crucially, this autoimmune attack begins years before symptoms like excessive thirst, frequent urination, and weight loss appear. This prolonged pre-symptomatic phase is where the opportunity for intervention lies.

For years, researchers have known about the presence of pancreatic autoantibodies – immune markers that signal this early attack. Simple blood tests, requiring only a few drops of blood from a finger prick, can detect these autoantibodies, revealing whether the immune system has begun to target the pancreas. Identifying individuals at this stage isn’t just about early diagnosis; it’s about potentially delaying disease progression and avoiding dangerous complications like diabetic ketoacidosis (DKA), a life-threatening emergency that can occur at the time of diagnosis.

Who Shoudl be Tested? The Role of Genetics and Risk Scores

With type 1 diabetes affecting approximately one in 200 people, determining who to test is a key challenge. Unlike many inherited diseases caused by a single gene mutation (like cystic fibrosis), type 1 diabetes is a complex condition influenced by a multitude of genes. Each gene contributes a small increase or decrease in risk.genetic predisposition alone isn’t enough; environmental factors also play a crucial, yet still largely unknown, role in triggering the disease.

Currently, testing is often focused on relatives of individuals with type 1 diabetes, as they have a higher risk. However, nine in ten people who develop type 1 diabetes have no family history. This highlights the need for broader, more refined screening methods.

Exciting research from the University of Exeter suggests a promising solution: combining genetic factors into a single risk score. This score could help predict who is most likely to develop type 1 diabetes, allowing for targeted monitoring of high-risk babies and children. As genomic screening becomes more widespread, this approach could become an invaluable tool for early detection.https://pubmed.ncbi.nlm.nih.gov/26577414/

Teplizumab: A Breakthrough in Immune Modulation

the most meaningful recent advancement is the approval of teplizumab, a therapy designed to intervene in the autoimmune process. Teplizumab isn’t a cure, but it can significantly delay the onset of stage 3 type 1 diabetes – the stage requiring lifelong insulin therapy – in individuals who have already developed stage 2 disease (presence of autoantibodies but no symptoms).

Clinical trials have shown that teplizumab can delay the need for insulin by up to three years in some individuals. While this may seem like a modest timeframe, it represents a substantial advancement in quality of life, particularly for children, offering them more years without the daily burden of insulin injections and the associated complications. It also provides a window of opportunity for further research into preventative strategies.

A Paradigm Shift in Diabetes Care

we are witnessing a fundamental shift in how we approach type 1 diabetes. For generations, management has been the primary focus.Now, the emphasis is turning towards prevention, aiming to stop the disease before irreversible damage occurs.

The future of type 1 diabetes care lies in a multi-pronged approach: early detection through autoantibody screening and genetic risk scores, coupled with therapies like teplizumab that modulate the immune system. Ongoing research is exploring other immunotherapies and strategies to protect insulin-producing cells, with the ultimate goal of achieving long-term remission and an insulin-free life for those at risk. This isn’t just about delaying the inevitable; it’s about potentially preventing it altogether.

Richard Oram, Professor of Diabetes and Nephrology, University of Exeter and Nicholas Thomas, Clinical Lecturer, Diabetes and Endocrinology, University of Exeter

This article is republished from The Conversation under a Creative Commons license. Read the original article. [https://theconversation.com/new-therapy-teplizumab-could-delay-type-1-diabetes-by-years-if-caught-early-259